Citius Oncology, Inc.
Citius Oncology, Inc. (CTOR) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Citius Oncology, Inc. (CTOR), covering cash flow, earnings, and balance sheets.
Citius Oncology, Inc. (CTOR) Income Statement & Financial Overview
Analyze Citius Oncology, Inc.’s CTOR earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $1.26M | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $5.13M | $0.00 | $0.00 | $0.00 |
| Operating Expenses | $6.39M | $0.00 | $0.00 | $0.00 |
| Total Costs & Expenses | $6.39M | $0.00 | $0.00 | $0.00 |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $0.00 | $0.00 | $0.00 |
| EBITDA | -$6.39M | $0.00 | $0.00 | $0.00 |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | -$6.39M | $0.00 | $0.00 | $0.00 |
| Income Before Tax | -$6.39M | $0.00 | $0.00 | $0.00 |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $264240.00 | $6813.00 | $4773.00 | $4836.00 |
| Net Income | -$6.66M | $0.00 | $0.00 | $0.00 |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.09 | $0.00 | $0.00 | $0.00 |
| Diluted EPS | -$0.09 | $0.00 | $0.00 | $0.00 |
| Weighted Avg Shares Outstanding | $71.55M | $71.55M | $66.53M | $66.53M |
| Weighted Avg Shares Outstanding (Diluted) | $71.55M | $71.55M | $66.53M | $66.53M |
Over the past four quarters, Citius Oncology, Inc. demonstrated steady revenue growth, increasing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Operating income reached $0.00 in Q1 2025, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$6.39M, reflecting operational efficiency. Net income dropped to -$6.66M, with EPS at -$0.09. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan